TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Jun 30, 2026. Filed Jul 29, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Jul 29, 2026

TEVA$42.61+2.0%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated statements of changes in equity

	Teva shareholders’ equity
	Ordinary shares
	Number ofshares (inmillions)	Statedvalue	Additionalpaid-incapital	Retainedearnings(accumulateddeficit)	Accumulated othercomprehensive(loss)	Treasuryshares	Total Tevashareholders’equity	Non-controllinginterests	Totalequity
(U.S. dollars in millions)
Balance at March 31, 2026	1,271	59	28,203	(13,394)	(2,512)	(4,128)	8,228	4	8,232
Net Income (loss)				(576)			(576)	*	(575)
Other comprehensive income (loss)					47		47	*	47
Stock-based compensation expense			40				40		40
Proceeds from exercise of options			13				13		13
Balance at June 30, 2026	1,271	$59	$28,256	$(13,969)	$(2,465)	$(4,128)	$7,753	$4	$7,757

*	Represents an amount less than $0.5 million.

	Teva shareholders’ equity
	Ordinary shares
	Number ofshares (inmillions)	Statedvalue	Additionalpaid-incapital	Retainedearnings(accumulateddeficit)	Accumulated othercomprehensive(loss)	Treasuryshares	Total Tevashareholders’equity	Non-controllinginterests	Totalequity
(U.S. dollars in millions)
Balance at December 31, 2025	1,256	58	28,133	(13,762)	(2,391)	(4,128)	7,910	4	7,914
Net Income (loss)				(207)			(207)	*	(206)
Other comprehensive income (loss)					(74)		(74)	*	(74)
Issuance of Shares	15	*	*
Stock-based compensation expense			83				83		83
Proceeds from exercise of options			39				39		39
Balance at June 30, 2026	1,271	$59	$28,256	$(13,969)	$(2,465)	$(4,128)	$7,753	$4	$7,757

*	Represents an amount less than $0.5 million.

	Teva shareholders’ equity
	Ordinary shares
	Number ofshares (inmillions)	Statedvalue	Additionalpaid-incapital	Retainedearnings(accumulateddeficit)	Accumulated othercomprehensive(loss)	Treasuryshares	Total Tevashareholders’equity	Non-controllinginterests	Totalequity
(U.S. dollars in millions)
Balance at March 31, 2025	1,253	58	27,965	(14,958)	(2,675)	(4,128)	6,262	7	6,269
Net Income (loss)				282			282	*	283
Other comprehensive income (loss)					244		244	*	244
Stock-based compensation expense			38				38		38
Balance at June 30, 2025	1,253	$58	$28,003	$(14,676)	$(2,431)	$(4,128)	$6,827	$7	$6,834

*	Represents an amount less than $0.5 million.

	Teva shareholders’ equity
	Ordinary shares
	Number ofshares (inmillions)	Statedvalue	Additionalpaid-incapital	Retainedearnings(accumulateddeficit)	Accumulated othercomprehensive(loss)	Treasuryshares	Total Tevashareholders’equity	Non-controllinginterests	Totalequity
(U.S. dollars in millions)
Balance at December 31, 2024	1,240	58	27,764	(15,173)	(3,148)	(4,128)	5,373	7	5,380
Net Income (loss)				497			497	*	497
Other comprehensive income (loss)					717		717	*	717
Issuance of Shares	13	*	*
Proceeds from exercise of options			3				3		3
Stock-based compensation expense			72				72		72
Purchase of shares from non-controlling interests**			165				165		165
Balance at June 30, 2025	1,253	$58	$28,003	$(14,676)	$(2,431)	$(4,128)	$6,827	$7	$6,834

*	Represents an amount less than $0.5 million.

**	In connection with the sale of Teva’s business venture in Japan.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.